Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference

Kidney International

Volumn 91, Issue 3, 2017, Pages 539-551

  Goodship, Timothy H J ^a   Cook, H Terence ^b   Fakhouri, Fadi ^c   Fervenza, Fernando C ^d   Frémeaux Bacchi, Véronique ^e   Kavanagh, David ^a   Nester, Carla M ^f   Noris, Marina ^g   Pickering, Matthew C ^b   Rodríguez de Córdoba, Santiago ^h   Roumenina, Lubka T ^i,j,k   Sethi, Sanjeev ^d   Smith, Richard J H ^f   Alpers, Charlie E ^l   Appel, Gerald B ^l   Ardissino, Gianluigi ^l   Ariceta, Gema ^l   Arici, Mustafa ^l   Bagga, Arvind ^l   Bajema, Ingeborg M ^l   Blasco, Miguel ^l   Burke, Linda ^l   Cairns, Thomas D ^l   Carratala, Mireya ^l   D'Agati, Vivette D ^l   Daha, Mohamed R ^l   De Vriese, An S ^l   Dragon Durey, Marie Agnès ^l   Fogo, Agnes B ^l   Galbusera, Miriam ^l   Gale, Daniel P ^l   Haller, Hermann ^l   Johnson, Sally ^l   Józsi, Mihály ^l   Karpman, Diana ^l   Lanning, Lynne ^l   Le Quintrec, Moglie ^l   Licht, Christoph ^l   Loirat, Chantal ^l   Monfort, Francisco ^l   Morgan, B Paul ^l   Noël, Laure Hélène ^l   O'Shaughnessy, Michelle M ^l   Rabant, Marion ^l   Rondeau, Eric ^l   Ruggenenti, Piero ^l   Sheerin, Neil S ^l   Smith, Jenna ^l   Spoleti, Fabrizio ^l   Thurman, Joshua M ^l   van de Kar, Nicole C A J ^l   Vivarelli, Marina ^l   Zipfel, Peter F ^l   more..

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c NANTES UNIVERSITY HOSPITAL   (France)

^d MAYO CLINIC   (United States)

^e HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^f UNIVERSITY OF IOWA   (United States)

^g MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^h CSIC   (Spain)

ⁱ INSERM   (France)

^j UNIVERSITÉ PARIS DESCARTES   (France)

^k SORBONNE UNIVERSITÉ   (France)

^l NONE

more..

Author keywords

anti complement therapies; atypical hemolytic uremic syndrome; C3 glomerulopathy; complement; glomerulonephritis; kidney disease

Indexed keywords

COMPLEMENT COMPONENT C3; ECULIZUMAB; C3 PROTEIN, HUMAN; COMPLEMENT INHIBITOR;

ACUTE DISEASE; C3 GLOMERULOPATHY; CHRONIC DISEASE; CLINICAL ASSESSMENT; CLINICAL FEATURE; CLINICAL TRIAL (TOPIC); CONFERENCE PAPER; EVIDENCE BASED MEDICINE; GENETIC PREDISPOSITION; GENETIC RISK; GENETIC SCREENING; GENETIC VARIABILITY; GLOMERULOPATHY; HEMOLYTIC UREMIC SYNDROME; HUMAN; KIDNEY TRANSPLANTATION; LABORATORY TEST; MEDICAL EXPERT; MICROANGIOPATHY; OUTCOME ASSESSMENT; PATIENT CARE; PHENOTYPE; PRACTICE GUIDELINE; RISK ASSESSMENT; RISK FACTOR; ANIMAL; ATYPICAL HEMOLYTIC UREMIC SYNDROME; COMPLEMENT ACTIVATION; DRUG EFFECTS; GENETICS; GLOMERULONEPHRITIS; IMMUNOLOGY; KIDNEY; PATHOLOGY; TREATMENT OUTCOME;

ANIMALS; ATYPICAL HEMOLYTIC UREMIC SYNDROME; COMPLEMENT ACTIVATION; COMPLEMENT C3; COMPLEMENT INACTIVATING AGENTS; GENETIC PREDISPOSITION TO DISEASE; GLOMERULONEPHRITIS; HUMANS; KIDNEY; PHENOTYPE; RISK FACTORS; TREATMENT OUTCOME;

EID: 85007574208     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1016/j.kint.2016.10.005     Document Type: Conference Paper

References (114)

1. 1 Chua, J.S., Baelde, H.J., Zandbergen, M., et al. Complement factor C4d is a common denominator in thrombotic microangiopathy. J Am Soc Nephrol 26 (2015), 2239–2247.
2. 2 Pickering, M.C., D'Agati, V.D., Nester, C.M., et al. C3 glomerulopathy: consensus report. Kidney Int 84 (2013), 1079–1089.
3. 3 Hou, J., Markowitz, G.S., Bomback, A.S., et al. Toward a working definition of C3 glomerulopathy by immunofluorescence. Kidney Int 85 (2014), 450–456.
4. 4 Larsen, C.P., Ambuzs, J.M., Bonsib, S.M., et al. Membranous-like glomerulopathy with masked IgG kappa deposits. Kidney Int 86 (2014), 154–161.
5. 5 Larsen, C.P., Messias, N.C., Walker, P.D., et al. Membranoproliferative glomerulonephritis with masked monotypic immunoglobulin deposits. Kidney Int 88 (2015), 867–873.
6. 6 Cook, H.T., C4d staining in the diagnosis of C3 glomerulopathy. J Am Soc Nephrol 26 (2015), 2609–2611.
7. 7 Sethi, S., Nasr, S.H., De Vriese, A.S., et al. C4d as a diagnostic tool in proliferative GN. J Am Soc Nephrol 26 (2015), 2852–2859.
8. 8 West, C.D., Witte, D.P., McAdams, A.J., Composition of nephritic factor-generated glomerular deposits in membranoproliferative glomerulonephritis type 2. Am J Kidney Dis 37 (2001), 1120–1130.
9. 9 Sethi, S., Fervenza, F.C., Zhang, Y., et al. C3 glomerulonephritis: clinicopathological findings, complement abnormalities, glomerular proteomic profile, treatment, and follow-up. Kidney Int 82 (2012), 465–473.
10. 10 Sethi, S., Gamez, J.D., Vrana, J.A., et al. Glomeruli of Dense Deposit Disease contain components of the alternative and terminal complement pathway. Kidney Int 75 (2009), 952–960.
11. 11 Loirat, C., Fakhouri, F., Ariceta, G., et al. An international consensus approach to the management of atypical hemolytic uremic syndrome in children. Pediatr Nephrol 31 (2016), 15–39.
12. 12 Caprioli, J., Noris, M., Brioschi, S., et al. Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. Blood 108 (2006), 1267–1279.
13. 13 Kavanagh, D., Goodship, T.H., Richards, A., Atypical hemolytic uremic syndrome. Semin Nephrol 33 (2013), 508–530.
14. 14 Sansbury, F.H., Cordell, H.J., Bingham, C., et al. Factors determining penetrance in familial atypical haemolytic uraemic syndrome. J Med Genet 51 (2014), 756–764.
15. 15 Bresin, E., Rurali, E., Caprioli, J., et al. Combined complement gene mutations in atypical hemolytic uremic syndrome influence clinical phenotype. J Am Soc Nephrol 24 (2013), 475–486.
16. 16 Noris, M., Remuzzi, G., Hemolytic uremic syndrome. J Am Soc Nephrol 16 (2005), 1035–1050.
17. 17 Servais, A., Noel, L.H., Roumenina, L.T., et al. Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies. Kidney Int 82 (2012), 454–464.
18. 18 Fervenza, F.C., Smith, R.J., Sethi, S., Association of a novel complement factor H mutation with severe crescentic and necrotizing glomerulonephritis. Am J Kidney Dis 60 (2012), 126–132.
19. 19 Sandhu, G., Bansal, A., Ranade, A., et al. C3 glomerulopathy masquerading as acute postinfectious glomerulonephritis. Am J Kidney Dis 60 (2012), 1039–1043.
20. 20 Vernon, K.A., Goicoechea de Jorge, E., Hall, A.E., et al. Acute presentation and persistent glomerulonephritis following streptococcal infection in a patient with heterozygous complement factor H-related protein 5 deficiency. Am J Kidney Dis 60 (2012), 121–125.
21. 21 Yu, Y., Triebwasser, M.P., Wong, E.K., et al. Whole-exome sequencing identifies rare, functional CFH variants in families with macular degeneration. Hum Mol Genet 23 (2014), 5283–5293.
22. 22 Kavanagh, D., Yu, Y., Schramm, E.C., et al. Rare genetic variants in the CFI gene are associated with advanced age-related macular degeneration and commonly result in reduced serum factor I levels. Hum Mol Genet 24 (2015), 3861–3870.
23. 23 Recalde, S., Tortajada, A., Subias, M., et al. Molecular Basis of Factor H R1210C Association with Ocular and Renal Diseases. J Am Soc Nephrol 27 (2016), 1305–1311.
24. 24 Misra, A., Peethambaram, A., Garg, A., Clinical features and metabolic and autoimmune derangements in acquired partial lipodystrophy: report of 35 cases and review of the literature. Medicine (Baltimore) 83 (2004), 18–34.
25. 25 Dalvin, L.A., Fervenza, F.C., Sethi, S., Pulido, J.S., Shedding light on fundus drusen associated with membranoproliferative glomerulonephritis: breaking stereotypes of types I, II, and III. Retin Cases Brief Rep 10 (2016), 72–78.
26. 26 Duvall-Young, J., MacDonald, M.K., McKechnie, N.M., Fundus changes in (type II) mesangiocapillary glomerulonephritis simulating drusen: a histopathological report. Br J Ophthalmol 73 (1989), 297–302.
27. 27 Mathieson, P.W., Wurzner, R., Oliveria, D.B., et al. Complement-mediated adipocyte lysis by nephritic factor sera. J Exp Med 177 (1993), 1827–1831.
28. 28 Fritsche, L.G., Chen, W., Schu, M., et al. Seven new loci associated with age-related macular degeneration. Nat Genet 45 (2013), 433–439.
29. 29 Gerber, A., Karch, H., Allerberger, F., et al. Clinical course and the role of shiga toxin-producing Escherichia coli infection in the hemolytic-uremic syndrome in pediatric patients, 1997-2000, in Germany and Austria: a prospective study. J Infect Dis 186 (2002), 493–500.
30. 30 Angioi, A., Fervenza, F.C., Sethi, S., et al. Diagnosis of complement alternative pathway disorders. Kidney Int 89 (2016), 278–288.
31. 31 Zuber, J., Fakhouri, F., Roumenina, L.T., et al. Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies. Nat Rev Nephrol 8 (2012), 643–657.
32. 32 Bu, F., Borsa, N.G., Jones, M.B., et al. High-Throughput genetic testing for thrombotic microangiopathies and C3 glomerulopathies. J Am Soc Nephrol 27 (2016), 1245–1253.
33. 33 de Cordoba, S.R., Complement genetics and susceptibility to inflammatory disease. Lessons from genotype-phenotype correlations. Immunobiology 221 (2016), 709–714.
34. 34 Noris, M., Brioschi, S., Caprioli, J., et al. Familial haemolytic uraemic syndrome and an MCP mutation. Lancet 362 (2003), 1542–1547.
35. 35 Richards, A., Kemp, E.J., Liszewski, M.K., et al. Mutations in human complement regulator, membrane cofactor protein (CD46), predispose to development of familial hemolytic uremic syndrome. Proc Natl Acad Sci U S A 100 (2003), 12966–12971.
36. 36 Ault, B.H., Schmidt, B.Z., Fowler, N.L., et al. Human factor H deficiency. Mutations in framework cysteine residues and block in H protein secretion and intracellular catabolism. J Biol Chem 272 (1997), 25168–25175.
37. 37 Levy, M., Halbwachs-Mecarelli, L., Gubler, M.C., et al. H deficiency in two brothers with atypical dense intramembranous deposit disease. Kidney Int 30 (1986), 949–956.
38. 38 Martinez-Barricarte, R., Heurich, M., Valdes-Canedo, F., et al. Human C3 mutation reveals a mechanism of dense deposit disease pathogenesis and provides insights into complement activation and regulation. J Clin Invest 120 (2010), 3702–3712.
39. 39 Montes, T., Goicoechea de Jorge, E., Ramos, R., et al. Genetic deficiency of complement factor H in a patient with age-related macular degeneration and membranoproliferative glomerulonephritis. Mol Immunol 45 (2008), 2897–2904.
40. 40 Schejbel, L., Schmidt, I.M., Kirchhoff, M., et al. Complement factor H deficiency and endocapillary glomerulonephritis due to paternal isodisomy and a novel factor H mutation. Genes Immun 12 (2011), 90–99.
41. 41 Abarrategui-Garrido, C., Martinez-Barricarte, R., Lopez-Trascasa, M., et al. Characterization of complement factor H-related (CFHR) proteins in plasma reveals novel genetic variations of CFHR1 associated with atypical hemolytic uremic syndrome. Blood 114 (2009), 4261–4271.
42. 42 Delvaeye, M., Noris, M., De Vriese, A., et al. Thrombomodulin mutations in atypical hemolytic-uremic syndrome. N Engl J Med 361 (2009), 345–357.
43. 43 Fremeaux-Bacchi, V., Fakhouri, F., Garnier, A., et al. Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults. Clin J Am Soc Nephrol 8 (2013), 554–562.
44. 44 Lemaire, M., Fremeaux-Bacchi, V., Schaefer, F., et al. Recessive mutations in DGKE cause atypical hemolytic-uremic syndrome. Nat Genet 45 (2013), 531–536.
45. 45 Maga, T.K., Nishimura, C.J., Weaver, A.E., et al. Mutations in alternative pathway complement proteins in American patients with atypical hemolytic uremic syndrome. Hum Mutat 31 (2010), E1445–E1460.
46. 46 Noris, M., Remuzzi, G., Atypical hemolytic-uremic syndrome. N Engl J Med 361 (2009), 1676–1687.
47. 47 Esparza-Gordillo, J., Goicoechea de Jorge, E., Buil, A., et al. Predisposition to atypical hemolytic uremic syndrome involves the concurrence of different susceptibility alleles in the regulators of complement activation gene cluster in 1q32. Hum Mol Genet 14 (2005), 703–712.
48. 48 Challis, R.C., Araujo, G.S., Wong, E.K., et al. A de novo deletion in the regulators of complement activation cluster producing a hybrid complement factor H/complement factor H-related 3 gene in atypical hemolytic uremic syndrome. J Am Soc Nephrol 27 (2016), 1617–1624.
49. 49 Chen, Q., Wiesener, M., Eberhardt, H.U., et al. Complement factor H-related hybrid protein deregulates complement in dense deposit disease. J Clin Invest 124 (2014), 145–155.
50. 50 Gale, D.P., de Jorge, E.G., Cook, H.T., et al. Identification of a mutation in complement factor H-related protein 5 in patients of Cypriot origin with glomerulonephritis. Lancet 376 (2010), 794–801.
51. 51 Tortajada, A., Yebenes, H., Abarrategui-Garrido, C., et al. C3 glomerulopathy-associated CFHR1 mutation alters FHR oligomerization and complement regulation. J Clin Invest 123 (2013), 2434–2446.
52. 52 Valoti, E., Alberti, M., Tortajada, A., et al. A novel atypical hemolytic uremic syndrome-associated hybrid CFHR1/CFH gene encoding a fusion protein that antagonizes factor H-dependent complement regulation. J Am Soc Nephrol 26 (2015), 209–219.
53. 53 Venables, J.P., Strain, L., Routledge, D., et al. Atypical haemolytic uraemic syndrome associated with a hybrid complement gene. PLoS Med, 3, 2006, e431.
54. 54 Athanasiou, Y., Voskarides, K., Gale, D.P., et al. Familial C3 glomerulopathy associated with CFHR5 mutations: clinical characteristics of 91 patients in 16 pedigrees. Clin J Am Soc Nephrol 6 (2011), 1436–1446.
55. 55 Chauvet, S., Roumenina, L.T., Bruneau, S., et al. A familial C3GN secondary to defective C3 regulation by complement receptor 1 and factor H. J Am Soc Nephrol 27 (2016), 1665–1677.
56. 56 Noris, M., Remuzzi, G., Managing and preventing atypical hemolytic uremic syndrome recurrence after kidney transplantation. Curr Opin Nephrol Hypertens 22 (2013), 704–712.
57. 57 Richards, S., Aziz, N., Bale, S., et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 17 (2015), 405–424.
58. 58 Frimat, M., Tabarin, F., Dimitrov, J.D., et al. Complement activation by heme as a secondary hit for atypical hemolytic uremic syndrome. Blood 122 (2013), 282–292.
59. 59 Goicoechea de Jorge, E., Harris, C.L., Esparza-Gordillo, J., et al. Gain-of-function mutations in complement factor B are associated with atypical hemolytic uremic syndrome. Proc Natl Acad Sci U S A 104 (2007), 240–245.
60. 60 Manuelian, T., Hellwage, J., Meri, S., et al. Mutations in factor H reduce binding affinity to C3b and heparin and surface attachment to endothelial cells in hemolytic uremic syndrome. J Clin Invest 111 (2003), 1181–1190.
61. 61 Marinozzi, M.C., Vergoz, L., Rybkine, T., et al. Complement factor B mutations in atypical hemolytic uremic syndrome-disease-relevant or benign?. J Am Soc Nephrol 25 (2014), 2053–2065.
62. 62 Noris, M., Galbusera, M., Gastoldi, S., et al. Dynamics of complement activation in aHUS and how to monitor eculizumab therapy. Blood 124 (2014), 1715–1726.
63. 63 Perez-Caballero, D., Gonzalez-Rubio, C., Gallardo, M.E., et al. Clustering of missense mutations in the C-terminal region of factor H in atypical hemolytic uremic syndrome. Am J Hum Genet 68 (2001), 478–484.
64. 64 Roumenina, L.T., Jablonski, M., Hue, C., et al. Hyperfunctional C3 convertase leads to complement deposition on endothelial cells and contributes to atypical hemolytic uremic syndrome. Blood 114 (2009), 2837–2845.
65. 65 Sanchez-Corral, P., Perez-Caballero, D., Huarte, O., et al. Structural and functional characterization of factor H mutations associated with atypical hemolytic uremic syndrome. Am J Hum Genet 71 (2002), 1285–1295.
66. 66 Schramm, E.C., Roumenina, L.T., Rybkine, T., et al. Mapping interactions between complement C3 and regulators using mutations in atypical hemolytic uremic syndrome. Blood 125 (2015), 2359–2369.
67. 67 Stahl, A.L., Vaziri-Sani, F., Heinen, S., et al. Factor H dysfunction in patients with atypical hemolytic uremic syndrome contributes to complement deposition on platelets and their activation. Blood 111 (2008), 5307–5315.
68. 68 Bernabeu-Herrero, M.E., Jimenez-Alcazar, M., Anter, J., et al. Complement factor H, FHR-3 and FHR-1 variants associate in an extended haplotype conferring increased risk of atypical hemolytic uremic syndrome. Mol Immunol 67 (2015), 276–286.
69. 69 Caprioli, J., Castelletti, F., Bucchioni, S., et al. Complement factor H mutations and gene polymorphisms in haemolytic uraemic syndrome: the C-257T, the A2089G and the G2881T polymorphisms are strongly associated with the disease. Hum Mol Genet 12 (2003), 3385–3395.
70. 70 Harris, C.L., Heurich, M., Rodriguez de Cordoba, S., et al. The complotype: dictating risk for inflammation and infection. Trends Immunol 33 (2012), 513–521.
71. 71 Pickering, M.C., de Jorge, E.G., Martinez-Barricarte, R., et al. Spontaneous hemolytic uremic syndrome triggered by complement factor H lacking surface recognition domains. J Exp Med 204 (2007), 1249–1256.
72. 72 Noris, M., Caprioli, J., Bresin, E., et al. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol 5 (2010), 1844–1859.
73. 73 Sanchez Chinchilla, D., Pinto, S., Hoppe, B., et al. Complement mutations in diacylglycerol kinase-epsilon-associated atypical hemolytic uremic syndrome. Clin J Am Soc Nephrol 9 (2014), 1611–1619.
74. 74 Abrera-Abeleda, M.A., Nishimura, C., Frees, K., et al. Allelic variants of complement genes associated with dense deposit disease. J Am Soc Nephrol 22 (2011), 1551–1559.
75. 75 Barbour, T.D., Ruseva, M.M., Pickering, M.C., Update on C3 glomerulopathy. Nephrol Dial Transplant 31 (2016), 717–725.
76. 76 Goicoechea de Jorge, E., Caesar, J.J., Malik, T.H., et al. Dimerization of complement factor H-related proteins modulates complement activation in vivo. Proc Natl Acad Sci U S A 110 (2013), 4685–4690.
77. 77 Licht, C., Heinen, S., Jozsi, M., et al. Deletion of Lys224 in regulatory domain 4 of Factor H reveals a novel pathomechanism for dense deposit disease (MPGN II). Kidney Int 70 (2006), 42–50.
78. 78 Wong, E.K., Anderson, H.E., Herbert, A.P., et al. Characterization of a factor H mutation that perturbs the alternative pathway of complement in a family with membranoproliferative GN. J Am Soc Nephrol 25 (2014), 2425–2433.
79. 79 Legendre, C.M., Licht, C., Muus, P., et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med 368 (2013), 2169–2181.
80. 80 Mannucci, P.M., Cugno, M., The complex differential diagnosis between thrombotic thrombocytopenic purpura and the atypical hemolytic uremic syndrome: Laboratory weapons and their impact on treatment choice and monitoring. Thromb Res 136 (2015), 851–854.
81. 81 Donne, R.L., Abbs, I., Barany, P., et al. Recurrence of hemolytic uremic syndrome after live related renal transplantation associated with subsequent de novo disease in the donor. Am J Kidney Dis, 40, 2002, E22.
82. 82 Povey, H., Vundru, R., Junglee, N., et al. Renal recovery with eculizumab in atypical hemolytic uremic syndrome following prolonged dialysis. Clin Nephrol 82 (2014), 326–331.
83. 83 Tarshish, P., Bernstein, J., Tobin, J.N., et al. Treatment of mesangiocapillary glomerulonephritis with alternate-day prednisone–a report of the International Study of Kidney Disease in Children. Pediatr Nephrol 6 (1992), 123–130.
84. 84 Licht, C., Greenbaum, L.A., Muus, P., et al. Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies. Kidney Int 87 (2015), 1061–1073.
85. 85 Coppo, R., Bonaudo, R., Peruzzi, R.L., et al. Liver transplantation for aHUS: still needed in the eculizumab era?. Pediatr Nephrol 31 (2016), 759–768.
86. 86 Rabasco, C., Cavero, T., Roman, E., et al. Effectiveness of mycophenolate mofetil in C3 glomerulonephritis. Kidney Int 88 (2015), 1153–1160.
87. 87 Besbas, N., Gulhan, B., Gucer, S., et al. A novel CFHR5 mutation associated with C3 glomerulonephritis in a Turkish girl. J Nephrol 27 (2014), 457–460.
88. 88 Bomback, A.S., Smith, R.J., Barile, G.R., et al. Eculizumab for dense deposit disease and C3 glomerulonephritis. Clin J Am Soc Nephrol 7 (2012), 748–756.
89. 89 Bonucchi, D., Leonelli, M., Damiano, F., et al. [Post-transplant recurrence of glomerulonephritis: a complex clinical case]. G Ital Nefrol 27 Suppl 52 (2010), S82–S84.
90. 90 Daina, E., Noris, M., Remuzzi, G., Eculizumab in a patient with dense-deposit disease. N Engl J Med 366 (2012), 1161–1163.
91. 91 Garnier, A.S., Augusto, J.F., Pellier, I., et al. Successful long-term outcome of kidney transplantation in a patient with X-linked thrombocytopenia: 9-year follow-up. Transplantation 98 (2014), e57–e58.
92. 92 Gurkan, S., Fyfe, B., Weiss, L., et al. Eculizumab and recurrent C3 glomerulonephritis. Pediatr Nephrol 28 (2013), 1975–1981.
93. 93 Herlitz, L.C., Bomback, A.S., Markowitz, G.S., et al. Pathology after eculizumab in dense deposit disease and C3 GN. J Am Soc Nephrol 23 (2012), 1229–1237.
94. 94 Inman, M., Prater, G., Fatima, H., et al. Eculizumab-induced reversal of dialysis-dependent kidney failure from C3 glomerulonephritis. Clin Kidney J 8 (2015), 445–448.
95. 95 Kerns, E., Rozansky, D., Troxell, M.L., Evolution of immunoglobulin deposition in C3-dominant membranoproliferative glomerulopathy. Pediatr Nephrol 28 (2013), 2227–2231.
96. 96 Le Quintrec, M., Lionet, A., Kandel, C., et al. Eculizumab for treatment of rapidly progressive C3 glomerulopathy. Am J Kidney Dis 65 (2015), 484–489.
97. 97 McCaughan, J.A., O'Rourke, D.M., Courtney, A.E., Recurrent dense deposit disease after renal transplantation: an emerging role for complementary therapies. Am J Transplant 12 (2012), 1046–1051.
98. 98 Oosterveld, M.J., Garrelfs, M.R., Hoppe, B., et al. Eculizumab in pediatric Dense Deposit Disease. Clin J Am Soc Nephrol 10 (2015), 1773–1782.
99. 99 Ozkaya, O., Nalcacioglu, H., Tekcan, D., et al. Eculizumab therapy in a patient with dense-deposit disease associated with partial lipodystropy. Pediatr Nephrol 29 (2014), 1283–1287.
100. 100 Radhakrishnan, S., Lunn, A., Kirschfink, M., et al. Eculizumab and refractory membranoproliferative glomerulonephritis. N Engl J Med 366 (2012), 1165–1166.
101. 101 Rousset-Rouviere, C., Cailliez, M., Garaix, F., et al. Rituximab fails where eculizumab restores renal function in C3nef-related DDD. Pediatr Nephrol 29 (2014), 1107–1111.
102. 102 Sanchez-Moreno, A., De la Cerda, F., Cabrera, R., et al. Eculizumab in dense-deposit disease after renal transplantation. Pediatr Nephrol 29 (2014), 2055–2059.
103. 103 Vivarelli, M., Pasini, A., Emma, F., Eculizumab for the treatment of dense-deposit disease. N Engl J Med 366 (2012), 1163–1165.
104. 104 Barbour, S.J., Espino-Hernandez, G., Reich, H.N., et al. The MEST score provides earlier risk prediction in lgA nephropathy. Kidney Int 89 (2016), 167–175.
105. 105 Cattran, D.C., Coppo, R., Cook, H.T., et al. The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification. Kidney Int 76 (2009), 534–545.
106. 106 Roberts, I.S., Cook, H.T., Troyanov, S., et al. The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility. Kidney Int 76 (2009), 546–556.
107. 107 Amornsiripanitch, N., Hong, S., Campa, M.J., et al. Complement factor H autoantibodies are associated with early stage NSCLC. Clin Cancer Res 16 (2010), 3226–3231.
108. 108 Dragon-Durey, M.A., Sethi, S.K., Bagga, A., et al. Clinical features of anti-factor H autoantibody-associated hemolytic uremic syndrome. J Am Soc Nephrol 21 (2010), 2180–2187.
109. 109 Khandelwal, P., Gupta, A., Sinha, A., et al. Effect of plasma exchange and immunosuppressive medications on antibody titers and outcome in anti-complement factor H antibody-associated hemolytic uremic syndrome. Pediatr Nephrol 30 (2015), 451–457.
110. 110 Sinha, A., Gulati, A., Saini, S., et al. Prompt plasma exchanges and immunosuppressive treatment improves the outcomes of anti-factor H autoantibody-associated hemolytic uremic syndrome in children. Kidney Int 85 (2014), 1151–1160.
111. 111 Sheerin, N.S., Kavanagh, D., Goodship, T.H., et al. A national specialized service in England for atypical haemolytic uraemic syndrome-the first year's experience. QJM 109 (2016), 27–33.
112. 112 Wetzels, J.F., van de Kar, N.C., Discontinuation of eculizumab maintenance treatment for atypical hemolytic uremic syndrome. Am J Kidney Dis, 65, 2015, 342.
113. 113 Ardissino, G., Possenti, I., Tel, F., et al. Discontinuation of eculizumab treatment in atypical hemolytic uremic syndrome: an update. Am J Kidney Dis 66 (2015), 172–173.
114. 114 Ardissino, G., Testa, S., Possenti, I., et al. Discontinuation of eculizumab maintenance treatment for atypical hemolytic uremic syndrome: a report of 10 cases. Am J Kidney Dis 64 (2014), 633–637.